INDIVIOR PLC/S (INVVY) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a hold rating to a buy rating in a research note released on Tuesday morning. They currently have $15.00 target price on the stock.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Separately, ValuEngine raised shares of INDIVIOR PLC/S from a sell rating to a hold rating in a research report on Tuesday, July 17th.

Shares of INVVY stock opened at $12.86 on Tuesday. The stock has a market cap of $1.74 billion, a PE ratio of 7.14, a PEG ratio of 0.58 and a beta of 0.83. INDIVIOR PLC/S has a twelve month low of $11.94 and a twelve month high of $33.83.

INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its quarterly earnings results on Thursday, July 26th. The company reported $0.45 earnings per share for the quarter. The firm had revenue of $268.00 million for the quarter. Analysts expect that INDIVIOR PLC/S will post 1.89 earnings per share for the current year.

INDIVIOR PLC/S Company Profile

Indivior PLC is a holding company, which engages in the manufacture and distribution of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, and Sublocade Injection. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Featured Story: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on INDIVIOR PLC/S (INVVY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with's FREE daily email newsletter.

Leave a Reply